P0J Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EDT
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.03
Previous CloseN/A
Volume0.00
Average Volume (3M)300.00
Market Cap
€19.32M
Enterprise Value€13.44M
Total Cash (Recent Filing)€1.53M
Total Debt (Recent Filing)€333.00K
Price to Earnings (P/E)―
Beta-2.41
Next Earnings
Oct 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,455,144,000
10 Day Avg. Volume300
30 Day Avg. Volume300
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)5.32
Price to Sales (P/S)6.11
P/FCF Ratio-3.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized Aptamer PlatformAptamer Group’s core capability in selecting and developing aptamers is a durable technological asset. Proprietary aptamer discovery know-how supports recurring service work, partner integrations and product components, creating long-term technical differentiation across diagnostics, research and therapeutic tooling.
Diversified End-market ApplicationsThe company’s aptamers address multiple structural markets—diagnostics, life-science research and potential therapeutics—reducing dependence on a single demand source. This multi-market applicability supports sustained addressable demand and multiple commercialization pathways over months to years.
Improved Leverage ManagementAn improved debt-to-equity profile and a stable equity ratio increase financial flexibility, lowering near-term solvency risk. Better leverage management can extend runway for R&D and partnership development, improving ability to fund strategic initiatives without immediate dilutive financing.
Bears Say
Severe Revenue DeclineA near-total revenue collapse materially reduces scale benefits, undermines customer credibility and makes fixed-cost recovery difficult. Sustained tiny revenue hampers ability to execute product rollouts, maintain partnerships, and reinvest in platform improvements over the next several months.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flows indicate ongoing cash burn and limited internal funding for development or commercialization. This forces reliance on external capital, increasing financing risk and potential dilution, and constrains strategic investments over a multi-month horizon.
Persistent Losses And Negative ROEChronic unprofitability and negative ROE signal structural challenges in converting technology into profitable operations. This reduces ability to attract investment on favorable terms, retain talent, and sustain long-term R&D spending without repeated external funding rounds.
Aptamer Group Plc News
P0J FAQ
What was Aptamer Group Plc’s price range in the past 12 months?
Aptamer Group Plc lowest stock price was <€0.01 and its highest was €0.03 in the past 12 months.
What is Aptamer Group Plc’s market cap?
Aptamer Group Plc’s market cap is €19.32M.
When is Aptamer Group Plc’s upcoming earnings report date?
Aptamer Group Plc’s upcoming earnings report date is Oct 20, 2026 which is in 95 days.
How were Aptamer Group Plc’s earnings last quarter?
Aptamer Group Plc released its earnings results on Mar 25, 2026. The company reported €0 earnings per share for the quarter, the consensus estimate of N/A by €0.
Is Aptamer Group Plc overvalued?
According to Wall Street analysts Aptamer Group Plc’s price is currently Overvalued.
Does Aptamer Group Plc pay dividends?
Aptamer Group Plc does not currently pay dividends.
What is Aptamer Group Plc’s EPS estimate?
Aptamer Group Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aptamer Group Plc have?
Aptamer Group Plc has 3,455,144,000 shares outstanding.
What happened to Aptamer Group Plc’s price movement after its last earnings report?
Aptamer Group Plc reported an EPS of €0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -13.043%.
Which hedge fund is a major shareholder of Aptamer Group Plc?
Currently, no hedge funds are holding shares in DE:P0J
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aptamer Group Plc
Aptamer Group plc, an international company headquartered in York, United Kingdom, specializes in providing advanced binders for applications spanning research, diagnostics, and therapeutics. Their innovative binder technology is engineered to resolve challenges often associated with traditional molecular tools, such as antibodies, offering crucial solutions to bioprocessing, diagnostic, and pharmaceutical scientists. Established in 2014, the company primarily serves pharmaceutical corporations, diagnostic development firms, and various research institutes.
Technical Analysis
Avacta Group plc
―
Bioventix
―
Oxford BioDynamics
―
Fusion Antibodies Plc
―
Arecor Therapeutics PLC
―